THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE FRONTLINEODP(TM) SYSTEM FOR PRODUCING A POINT OF CARE PLASMA PRODUCT FOR TRANSFUSION. THE SCOPE IS DEFINED IN THE SOW BELOW.
Definitive Contract · Office of Assistant Secretary for Preparedness and Response · to Velico Medical, Inc. (UEI PYD3XN5ZZPJ1) · data as of 2026-10-21
Obligated to date$107.29M19 actions
Current value$139.00Mwith options exercised
Potential value$156.73Mif every option is used
Period2021-08-02 → 2029-11-30up to 2031-11-30 with options
What it is
Product or service
Health R&D Services; Health Care - Other; Applied Research (PSC AN42)
Industry
Other Measuring and Controlling Device Manufacturing (NAICS 334519)
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
19 actions since 2022-12-13. Each is a modification or amendment with the money it added or took back.
Date
Modification
Kind
Amount
What the agency wrote
2026-09-01
P00021
Funding only
$3.39M
THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE SUPPLEMENTAL FUNDING FOR CLINS 0005, 0006, 0008, UPDATE ARTICLES B.2.2. OPTION COSTS, B.3. ADVANCED UNDERSTANDINGS, AND SECTION J - LIST OF ATTACHMENTS, ATTACHMENT 1 - STATEMENT OF WORK DATED AUGUST 1, 2
2026-08-21
P00020
Administrative change
$0
THE PURPOSE OF THIS ADMINISTRATIVE MODIFICATION IS TO CORRECT THE PERIOD OF PERFORMANCE FOR CLINS 0001, 0004, 0005, 0006, 0007, 0008, AND 0009 TO ALIGN WITH IPP.
2026-05-29
P00019
Administrative change
$0
THE PURPOSE OF THIS MODIFICATION IS TO UPDATE ARTICLE B.3 ADVANCED UNDERSTANDING, ITEM 6. SUBCONTRACTS AND CONSULTANTS, AND THE STATEMENT OF WORK DATED APRIL 16, 2026; AT NO ADDITIONAL COST TO THE GOVERNMENT.
2026-04-07
P00018
Administrative change
$0
FAR PART 43.103 - UNIATERAL MODIFICATION
2026-02-27
P00017
Option exercised
$35.00M
FAR PART 43.103(A) - BILATERAL MODIFICATION
2026-02-20
P00016
Administrative change
$0
THE PURPOSE OF THIS MODIFICATION IS TO CORRECT THE PERIOD OF PERFORMANCE FOR CLIN0008/OPTION 7 AND CLIN0004/OPTION 5 TO ALIGN WITH IPP.
2025-12-15
P00015
Administrative change
$0
THE PURPOSE OF THIS NO-COST EXTENSION MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE THROUGH FEBRUARY 28, 2026, FOR CLIN 0008/OPTION 7 FOR THE COMPLETION OF A SUCCESSFUL PHASE 1 CLINICAL STUDY CONTINUED SCALE UP, SUSTAINING, AND VERIFICATION TES
2025-08-04
P00014
Funding only
$3.30M
THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE SUPPLEMENTAL FUNDING FOR CLINS 0001, 0005, 0008, 0009, EXTEND THE PERIOD OF PERFORMANCE THROUGH JUNE 30, 2026, FOR CLINS 0004 AND 0005; AND CLIN 0009 THROUGH FEBRUARY 28, 2026, DUE TO DELAY IN COMPLETION
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-21). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗
2025-04-30
P00013
Administrative change
$0
THE PURPOSE OF THIS NO-COST EXTENSION MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE (POP) OF CLIN 0001 (BASE) AND CLIN 0004 (OPTION 3) TO 12/31/2025, UPDATE ARTICLES B.2.1 BASE PERIOD (CLIN 0001), B.2.2 OPTION COSTS (CLINS 0002-0009), B.3 ADVAN
2024-12-20
P00012
Administrative change
$0
THE PURPOSE OF THIS NO-COST EXTENSION MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE (POP) OF CLIN 0002 (OPTION 1) TO 2/28/2025 DUE TO THE DELAY IN COMPLETING THE DRYER/SEALER SCALE-UP AND MANUFACTURING, AND CLIN 0003 (OPTION 2) TO 3/31/2025 DUE
2024-08-22
P00011
Administrative change
$0
THE PURPOSE OF THIS NO-COST EXTENSION MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE (POP) OF CLIN 0001 (BASE) TO 6/30/2025, CLIN 0002 (OPTION 1) TO 12/31/2024, AND CLIN 0003 (OPTION 2) TO 12/31/2024.
2024-08-09
P00010
Administrative change
$0
THE PURPOSE OF THIS MODIFICATION IS TO CORRECT THE PERIOD OF PERFORMANCE TO ALIGN IPP FOR CLIN0005 (OPTION 4).
2024-04-12
P00009
Option exercised
$13.87M
THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE AND FUND OPTION 8/CLIN0009, PROVIDE SUPPLEMENTAL FUNDING FOR CLINS 0001, 0002, 0003, 0004, 0005, UPDATE SOW DATED 12/26/23, AND EXTEND THE PERIOD OF PERFORMANCE FOR CLIN0001 THROUGH DECEMBER 29, 2024, C
2024-03-25
P00008
Administrative change
$0
THE PURPOSE OF THIS NO-COST EXTENSION MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE (POP) OF CLIN 0002 (OPTION 1) TO 4/30/2024.
2023-12-15
P00007
Administrative change
$0
THE PURPOSE OF THIS NO-COST EXTENSION MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE (POP) OF CLIN 0002 (OPTION 1) TO 3/30/2024, CLIN 0003 (OPTION 2) TO 6/30/2024, AND CLIN 0004 (OPTION 3) TO 9/30/2024.
2023-09-05
P00006
Supplemental agreement (work within scope)
$2.80M
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE FRONTLINEODP(TM) SYSTEM FOR PRODUCING A POINT OF CARE PLASMA PRODUCT FOR TRANSFUSION. THE SCOPE IS DEFINED IN THE SOW BELOW.
2023-05-23
P00005
Option exercised
$41.25M
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE FRONTLINEODP(TM) SYSTEM FOR PRODUCING A POINT OF CARE PLASMA PRODUCT FOR TRANSFUSION. THE SCOPE IS DEFINED IN THE SOW BELOW.
2023-03-17
P00004
Supplemental agreement (work within scope)
$2.92M
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE FRONTLINEODP(TM) SYSTEM FOR PRODUCING A POINT OF CARE PLASMA PRODUCT FOR TRANSFUSION. THE SCOPE IS DEFINED IN THE SOW BELOW.
2022-12-13
P00003
Change order
$4.75M
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE FRONTLINEODP(TM) SYSTEM FOR PRODUCING A POINT OF CARE PLASMA PRODUCT FOR TRANSFUSION. THE SCOPE IS DEFINED IN THE SOW BELOW.